<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7320630</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btaa210</article-id>
    <article-id pub-id-type="publisher-id">btaa210</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Notes</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Databases and Ontologies</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Hongchun</given-names>
        </name>
        <xref ref-type="aff" rid="btaa210-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa210-aff3">b3</xref>
        <xref ref-type="author-notes" rid="btaa210-FM2"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pei</surname>
          <given-names>Fen</given-names>
        </name>
        <xref ref-type="aff" rid="btaa210-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa210-aff2">b2</xref>
        <xref ref-type="author-notes" rid="btaa210-FM2"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Taylor</surname>
          <given-names>D Lansing</given-names>
        </name>
        <xref ref-type="aff" rid="btaa210-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa210-aff2">b2</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9959-4176</contrib-id>
        <name>
          <surname>Bahar</surname>
          <given-names>Ivet</given-names>
        </name>
        <xref ref-type="corresp" rid="btaa210-cor1"/>
        <xref ref-type="aff" rid="btaa210-aff1">b1</xref>
        <xref ref-type="aff" rid="btaa210-aff2">b2</xref>
        <!--<email>bahar@pitt.edu</email>-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Lu</surname>
          <given-names>Zhiyong</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <aff id="btaa210-aff1">
      <label>b1</label>
      <institution>Department of Computational and Systems Biology School of Medicine</institution>
    </aff>
    <aff id="btaa210-aff2"><label>b2</label><institution>Drug Discovery Institute</institution>, University of Pittsburgh, Pittsburgh, PA 15213, <country country="US">USA</country></aff>
    <aff id="btaa210-aff3"><label>b3</label><institution>Research Center for Computer-Aided Drug Discovery, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences</institution>, Shenzhen 518055, <country country="CN">China</country></aff>
    <author-notes>
      <fn id="btaa210-FM2">
        <label>‡</label>
        <p>The authors wish it to be known that, in their opinion, Hongchun Li and Fen Pei should be regarded as Joint First Authors.</p>
      </fn>
      <corresp id="btaa210-cor1">To whom correspondence should be addressed. <email>bahar@pitt.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="epub" iso-8601-date="2020-03-28">
      <day>28</day>
      <month>3</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>15</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>28</day>
      <month>3</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>36</volume>
    <issue>12</issue>
    <fpage>3935</fpage>
    <lpage>3937</lpage>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>11</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>04</day>
        <month>2</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>3</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btaa210.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>QuartataWeb is a user-friendly server developed for polypharmacological and chemogenomics analyses. Users can easily obtain information on experimentally verified (known) and computationally predicted (new) interactions between 5494 drugs and 2807 human proteins in DrugBank, and between 315 514 chemicals and 9457 human proteins in the STITCH database. In addition, QuartataWeb links targets to KEGG pathways and GO annotations, completing the bridge from drugs/chemicals to function via protein targets and cellular pathways. It allows users to query a series of chemicals, drug combinations or multiple targets, to enable multi-drug, multi-target, multi-pathway analyses, toward facilitating the design of polypharmacological treatments for complex diseases.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>QuartataWeb is freely accessible at <ext-link ext-link-type="uri" xlink:href="http://quartata.csb.pitt.edu">http://quartata.csb.pitt.edu</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref ref-type="supplementary-material" rid="sup1">Supplementary data</xref> are available at <italic>Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>P41 GM103712</award-id>
        <award-id>P30 DA035778</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>It is now widely accepted that many complex diseases are associated with multiple targets, which in turn affect multiple pathways, requiring the adoption of quantitative systems pharmacology (QSP) approaches for assessing the mechanisms of disease etiology, progression and treatment (<xref rid="btaa210-B13" ref-type="bibr">Stern <italic>et al.</italic>, 2016</xref>). The possibility of exploiting the promiscuity of drugs via drug repurposing and polypharmacological treatments also emerged in recent years as a means of reducing risk and cost in drug development (<xref rid="btaa210-B2" ref-type="bibr">Ashburn and Thor, 2004</xref>; <xref rid="btaa210-B9" ref-type="bibr">Pantziarka <italic>et al.</italic>, 2018</xref>; <xref rid="btaa210-B12" ref-type="bibr">Sachs <italic>et al.</italic>, 2017</xref>). In parallel, chemogenomics studies assist in improving our understanding of disease mechanisms and developing therapeutic strategies by providing phenotypic information on ensembles of active compounds screened against families of targets. Such studies underscore the importance of developing computational tools that would harness the rapidly accumulating data to predict new chemical–target interactions (CTIs) over a broad space of chemicals and enable their mapping to pathways and function.</p>
    <p>Several resources have been developed in the last decade to address different aspects of the emerging needs but an integrated server designed to automate the association of multiple CTIs with enriched pathways and functions remains to be developed. For example, the servers SEA (<xref rid="btaa210-B7" ref-type="bibr">Keiser <italic>et al.</italic>, 2007</xref>), SwissTargetPrediction (<xref rid="btaa210-B4" ref-type="bibr">Daina <italic>et al.</italic>, 2019</xref>) and SuperPred (<xref rid="btaa210-B8" ref-type="bibr">Nickel <italic>et al.</italic>, 2014</xref>) predict new CTIs, but not corresponding pathways. DINIES (<xref rid="btaa210-B16" ref-type="bibr">Yamanishi <italic>et al.</italic>, 2014</xref>) and DT-Web (<xref rid="btaa210-B1" ref-type="bibr">Alaimo <italic>et al.</italic>, 2015</xref>) incorporate pathway information, but not large-scale CTIs, their respective data being limited to Kyoto Encyclopedia of Genes and Genomes (KEGG) (<xref rid="btaa210-B6" ref-type="bibr">Kanehisa <italic>et al.</italic>, 2017</xref>) and DrugBank (<xref rid="btaa210-B15" ref-type="bibr">Wishart <italic>et al.</italic>, 2018</xref>). Furthermore, existing interfaces are not designed to use as input multiple drugs/targets for polypharmacological strategies and/or for complementing chemogenomics efforts.</p>
    <p>We developed the QuartataWeb server to address those needs. QuartataWeb uses known (experimentally verified) CTIs from DrugBank and STITCH (<xref rid="btaa210-B14" ref-type="bibr">Szklarczyk <italic>et al.</italic>, 2016</xref>; <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref> and <xref ref-type="supplementary-material" rid="sup1">Fig. S1</xref>) in a probabilistic matrix factorization algorithm (<xref rid="btaa210-B3" ref-type="bibr">Cobanoglu <italic>et al.</italic>, 2013</xref>) to predict new CTIs in the extended space of more than 300 000 chemicals and 9000 human proteins. The engine parameters have been optimized (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S2</xref>) to ensure high CTI prediction accuracy (see <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S3</xref> and <xref ref-type="supplementary-material" rid="sup1">Fig. S2</xref>). The outputs are linked to KEGG pathways and Gene Ontology (GO) annotations (GOAs) (<xref rid="btaa210-B5" ref-type="bibr">Huntley <italic>et al.</italic>, 2015</xref>) to predict the most probable pathways, functions and processes affected by one or more chemicals and to efficiently assist in interpreting and/or guiding chemogenomics and polypharmacological studies.</p>
  </sec>
  <sec>
    <title>2 QuartataWeb implementation and pipeline</title>
    <p>The QuartataWeb server pipeline is schematically depicted in <xref ref-type="fig" rid="btaa210-F1">Figure 1A</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S4</xref>. The server can be flexibly queried with three types of input: (I) a list of chemicals (or targets) for chemogenomics-like screening <italic>in silico</italic> (<xref ref-type="fig" rid="btaa210-F1">Fig. 1A</xref>); (II) one or more pairs of chemicals to be administered in combination for polypharmacological purposes (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S4</xref>); and (III) a single chemical and/or a single target to be characterized (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S4</xref>). In response to a list of chemicals entered in Type I query, QuartataWeb releases newly predicted CTIs and chemical–chemical similarities based on pre-computed latent factor models learned from DrugBank or STITCH data, in addition to retrieving known CTIs from these datasets, as schematically described in <xref ref-type="fig" rid="btaa210-F1">Figure 1A</xref>. The outputted targets are then subjected to target enrichment, which also lead to enrichment scores for associated pathways and GOAs (<italic>P</italic>-values; see Supplementary Theory and Methods]. The same sequence of tasks can be carried out for a list of targets entered as input. In the case of Type II input, the same tasks are carried out for pairs of chemicals to obtain shared targets, and their enrichment, along with enriched pathways and GOAs (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S4</xref>). Type III input is the simplest query where users enter one chemical, one target or a chemical–target pair to identify associated CTIs, similar chemicals or targets, and enriched pathways and GOAs. Furthermore, the secondary interactions (2°, beyond the immediate neighbors) in the bipartite network of chemical/targets can be visualized. In all cases, outputs are presented as tables with several specifications (e.g. drug/chemical identifiers, Gene IDs and names, PDB IDs, confidence scores and enrichment <italic>P</italic>-values), in addition to visuals such as network representations, bar plots or heatmaps. The force-directed layout in JavaScript D3 package has been customized and designed to interactively display the CTIs and pathways networks.</p>
    <fig id="btaa210-F1" orientation="portrait" position="float">
      <label>Fig. 1.</label>
      <caption>
        <p>QuartataWeb workflow for Type I input, example outputs on CTIs, pathways and GOAs. (<bold>A</bold>) In Type I input, users enter either a list of chemicals or a list of targets of interest. Here, the workflow for a list of chemicals is illustrated. See details in the text. (<bold>B</bold>) Identification of targets (<italic>dark violet dots</italic>, in <italic>yellow ellipse</italic>) shared by four drugs (Input Type I) indicated by <italic>red nodes.</italic> (<bold>C</bold>) KEGG pathways (<italic>green boxes</italic>) corresponding to targets in (B). (<bold>D</bold>) Top 10 enriched GO molecular functions for targets in (B). Bar plot shows enrichment <italic>P</italic>-values. (<bold>E</bold>) Illustration of ligand–target interactions obtained by Type III input. Second generation of nodes with degrees &lt; 3 are hidden by applying ‘<italic>Trim 2nd generation nodes’</italic> button. (<bold>F</bold>) Chemical–chemical similarities. The option ‘<italic>Display secondary interactions</italic>’ displays targets shared by selected drugs (<italic>yellow</italic>)</p>
      </caption>
      <graphic xlink:href="btaa210f1"/>
    </fig>
  </sec>
  <sec>
    <title>3 Applications</title>
    <p><bold>Chemogenomics analysis for a list of chemicals</bold>. In many cases, a set of chemicals exhibiting comparable phenotypes are analyzed in phenotypic screening. Suppose, we are interested in finding out the common mechanism of action of this set of chemicals (Type I input). <xref ref-type="fig" rid="btaa210-F1">Figure 1B</xref> illustrates such a case where four drugs are inputted having same phenotype. QuartataWeb permits to identify the common targets along with the interaction confidence scores and enrichment scores of the targets. One may further learn about the pathways associated with the shared targets (<xref ref-type="fig" rid="btaa210-F1">Fig. 1C</xref>) and corresponding GOAs (<xref ref-type="fig" rid="btaa210-F1">Fig. 1D</xref>). The interface also provides tables with detailed information on the pathways and GOAs, including their <italic>P</italic>-values (<xref ref-type="supplementary-material" rid="sup1">Supplementary Fig. S5</xref>), which could help assessing the dominant pathways and processes that underlie the shared phenotype. Our recent QSP analysis of 50 drugs of abuse serves as an example of the utility of this type of integrated studies (<xref rid="btaa210-B11" ref-type="bibr">Pei <italic>et al.</italic>, 2019</xref>).</p>
    <p><bold>Polypharmacological evaluation of drug pairs</bold>. Similarly, <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S6</xref> illustrates the output from QuartataWeb for identifying common targets given pairs of chemicals (Type II input) that trigger comparable responses, e.g. aripiprazole/olanzapine, clozapine/trimipramine, methotrimeprazine/epinastine and cabergoline/mianserin. The corresponding CTIs are listed in tables, and also displayed in a network viewer with an interactive control panel. Links to pathways and GOAs result pages are indicated. In this example, 15 among 192 known and 80 predicted (confidence scores &gt; 0.9) targets were identified as common targets. Pathways shared by each chemical pair are also listed in the pathway enrichment table. This type of analysis applied to drug combinations used in a Huntington’s disease model helped elucidate the origin (shared pathways) of observed synergistic effects (<xref rid="btaa210-B10" ref-type="bibr">Pei <italic>et al.</italic>, 2017</xref>).</p>
    <p><bold>Drug repurposing or identification of side-effects (Type III)</bold>. Consider loxapine and its target, α2A adrenergic receptor (gene name: ADRA2A) as an example. CTIs corresponding to both drug (<italic>red sphere</italic>) and target (<italic>blue sphere</italic>) can be viewed in peacock representation (<xref ref-type="fig" rid="btaa210-F1">Fig. 1E</xref>), where known and predicted CTIs being distinguished by the <italic>gray</italic> and <italic>red</italic> edges, respectively. Users can interactively select nodes to view primary and 2° interactions. Loxapine is an antipsychotic agent approved for treating schizophrenia, whose primary targets are dopamine and serotonin receptors. The figure displays the 2° interactions of a serotonin receptor (HTR3C, node colored cyan) which turns out to be a target of many drugs associated ADRA2A, some of which are repurposable. Finally, Type III input also permits to identify similar drugs and shared targets as illustrated for the pair doxepin and loxapine (<xref ref-type="fig" rid="btaa210-F1">Fig. 1F</xref>).</p>
  </sec>
  <sec>
    <title>4 Conclusion</title>
    <p>We presented QuartataWeb, an integrated server that offers multiple capabilities for QSP analyses using both known associations and machine-learning predictions. We showed that the interface can help identify repurposable drugs, side-effects, enriched pathways, as well as shared functions, cellular processes and environment for different types of queries. QuartataWeb is expected to serve as a first filter toward designing more effective phenotypic screens and polypharmacological strategies.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sup1">
      <label>btaa210_Supplementary_Data</label>
      <media xlink:href="btaa210_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>The authors thank Dr Bing Liu for useful feedback.</p>
    <sec>
      <title>Funding</title>
      <p>Support by the National Institutes of Health awards [P41 GM103712 and P30 DA035778] is gratefully acknowledged by I.B.</p>
      <p><italic>Conflict of Interest</italic>: none declared.</p>
    </sec>
  </ack>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btaa210-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaimo</surname><given-names>S.</given-names></name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>DT-Web: a web-based application for drug-target interaction and drug combination prediction through domain-tuned network-based inference</article-title>. <source>BMC Syst. Biol</source>., <volume>9</volume>, <fpage>S4</fpage>.</mixed-citation>
    </ref>
    <ref id="btaa210-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburn</surname><given-names>T.T.</given-names></name>, <name name-style="western"><surname>Thor</surname><given-names>K.B.</given-names></name></person-group> (<year>2004</year>) 
<article-title>Drug repositioning: identifying and developing new uses for existing drugs</article-title>. <source>Nat. Rev. Drug Discov</source>., <volume>3</volume>, <fpage>673</fpage>–<lpage>683</lpage>.<pub-id pub-id-type="pmid">15286734</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cobanoglu</surname><given-names>M.C.</given-names></name></person-group><etal>et al</etal> (<year>2013</year>) 
<article-title>Predicting drug-target interactions using probabilistic matrix factorization</article-title>. <source>J. Chem. Inf. Model</source>, <volume>53</volume>, <fpage>3399</fpage>–<lpage>3409</lpage>.<pub-id pub-id-type="pmid">24289468</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules</article-title>. <source>Nucleic Acids Res</source>., <volume>47</volume>, <fpage>W357</fpage>–<lpage>W364</lpage>.<pub-id pub-id-type="pmid">31106366</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huntley</surname><given-names>R.P.</given-names></name></person-group><etal>et al</etal> (<year>2015</year>) 
<article-title>The GOA database: gene ontology annotation updates for 2015</article-title>. <source>Nucleic Acids Res</source>., <volume>43</volume>, <fpage>D1057</fpage>–<lpage>D1063</lpage>.<pub-id pub-id-type="pmid">25378336</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanehisa</surname><given-names>M.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Res</source>., <volume>45</volume>, <fpage>D353</fpage>–<lpage>D361</lpage>.<pub-id pub-id-type="pmid">27899662</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keiser</surname><given-names>M.J.</given-names></name></person-group><etal>et al</etal> (<year>2007</year>) 
<article-title>Relating protein pharmacology by ligand chemistry</article-title>. <source>Nat. Biotechnol</source>., <volume>25</volume>, <fpage>197</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">17287757</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickel</surname><given-names>J.</given-names></name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>SuperPred: update on drug classification and target prediction</article-title>. <source>Nucleic Acids Res</source>., <volume>42</volume>, <fpage>W26</fpage>–<lpage>W31</lpage>.<pub-id pub-id-type="pmid">24878925</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantziarka</surname><given-names>P.</given-names></name></person-group><etal>et al</etal> (<year>2018</year>) 
<article-title>ReDO_DB: the repurposing drugs in oncology database</article-title>. <source>Ecancermedicalscience</source>, <volume>12</volume>, <fpage>886</fpage>.<pub-id pub-id-type="pmid">30679953</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pei</surname><given-names>F.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>Connecting neuronal cell protective pathways and drug combinations in a Huntington’s disease model through the application of quantitative systems pharmacology</article-title>. <source>Sci. Rep</source>., <volume>7</volume>, <fpage>17803</fpage>.<pub-id pub-id-type="pmid">29259176</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pei</surname><given-names>F.</given-names></name></person-group><etal>et al</etal> (<year>2019</year>) 
<article-title>Quantitative systems pharmacological analysis of drugs of abuse reveals the pleiotropy of their targets and the effector role of mTORC1</article-title>. <source>Front. Pharmacol</source>., <volume>10</volume>, <fpage>191</fpage>.<pub-id pub-id-type="pmid">30906261</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachs</surname><given-names>R.E.</given-names></name></person-group><etal>et al</etal> (<year>2017</year>) 
<article-title>Encouraging new uses for old drugs</article-title>. <source>JAMA</source>, <volume>318</volume>, <fpage>2421</fpage>–<lpage>2422</lpage>.<pub-id pub-id-type="pmid">29204602</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>A.M.</given-names></name></person-group><etal>et al</etal> (<year>2016</year>) 
<article-title>A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine</article-title>. <source>J. Biomol. Screen</source>., <volume>21</volume>, <fpage>521</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">26962875</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szklarczyk</surname><given-names>D.</given-names></name></person-group><etal>et al</etal> (<year>2016</year>) 
<article-title>STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data</article-title>. <source>Nucleic Acids Res</source>., <volume>44</volume>, <fpage>D380</fpage>–<lpage>D384</lpage>.<pub-id pub-id-type="pmid">26590256</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><etal>et al</etal> (<year>2018</year>) 
<article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source>., <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="btaa210-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamanishi</surname><given-names>Y.</given-names></name></person-group><etal>et al</etal> (<year>2014</year>) 
<article-title>DINIES: drug-target interaction network inference engine based on supervised analysis</article-title>. <source>Nucleic Acids Res</source>., <volume>42</volume>, <fpage>W39</fpage>–<lpage>W45</lpage>.<pub-id pub-id-type="pmid">24838565</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
